CervoMed Inc. Files 8-K on Shareholder Nominations
Ticker: CRVO · Form: 8-K · Filed: Mar 18, 2024 · CIK: 1053691
| Field | Detail |
|---|---|
| Company | Cervomed Inc. (CRVO) |
| Form Type | 8-K |
| Filed Date | Mar 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing, shareholder-activism
TL;DR
CervoMed filed an 8-K for shareholder nominations & financials - board shakeup incoming?
AI Summary
CervoMed Inc. filed an 8-K on March 18, 2024, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11 and financial statements. The company, formerly known as Diffusion Pharmaceuticals Inc., RestorGenex Corp, and Stratus Media Group, Inc., is incorporated in Delaware and headquartered in Boston, MA.
Why It Matters
This filing indicates potential changes or activism related to the company's board of directors, which could impact its strategic direction and future performance.
Risk Assessment
Risk Level: medium — Shareholder nominations can signal dissatisfaction or a desire for strategic change, introducing uncertainty.
Key Numbers
- 001-37942 — SEC File Number (Identifies the company's filing with the SEC.)
- 30-0645032 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- CervoMed Inc. (company) — Registrant
- Diffusion Pharmaceuticals Inc. (company) — Former company name
- RestorGenex Corp (company) — Former company name
- Stratus Media Group, Inc (company) — Former company name
- 20240318 (date) — Filing date
- March 12, 2024 (date) — Date of earliest event reported
FAQ
What specific shareholder nominations were made?
The filing does not specify the names of the individuals nominated by shareholders, only that nominations were made pursuant to Exchange Act Rule 14a-11.
What are the key financial statements included in this filing?
The filing states that financial statements are included, but the specific details or nature of these statements are not elaborated upon in the provided text.
When was CervoMed Inc. previously known by other names?
CervoMed Inc. was formerly known as Diffusion Pharmaceuticals Inc. (name change effective 20160115), RestorGenex Corp (name change effective 20140307), and Stratus Media Group, Inc (name change effective 20080722).
What is the primary business of CervoMed Inc.?
CervoMed Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
What is the significance of Exchange Act Rule 14a-11?
Exchange Act Rule 14a-11 pertains to shareholder nominations for director positions, often indicating proxy contests or significant shareholder engagement.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-03-18 16:32:06
Key Financial Figures
- $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market
Filing Documents
- crvo20240318_8k.htm (8-K) — 29KB
- 0001437749-24-008315.txt ( ) — 158KB
- crvo-20240312.xsd (EX-101.SCH) — 3KB
- crvo-20240312_def.xml (EX-101.DEF) — 11KB
- crvo-20240312_lab.xml (EX-101.LAB) — 15KB
- crvo-20240312_pre.xml (EX-101.PRE) — 11KB
- crvo20240318_8k_htm.xml (XML) — 3KB
08 Shareholder Director Nominations
Item 5.08 Shareholder Director Nominations Annual Stockholders ' Meeting The board of directors (the "Board") of CervoMed Inc. (the "Company") has established June 14, 2024, as the date of the Company's 2024 annual meeting of stockholders (the "Annual Meeting"). Additional details regarding the Annual Meeting, which will be held virtually by means of remote communication, will be disclosed in the Company's definitive proxy statement for the Annual Meeting to be filed with the U.S. Securities and Exchange Commission ("SEC"). As the Company did not hold an annual meeting of stockholders in 2023, stockholders of the Company who wish to have a proposal, including nominations of persons for election to the Board and proposals under Rule 14a-8, considered for inclusion in the Company's proxy materials for the Annual Meeting must deliver such proposal by email to the Corporate Secretary at info@cervomed.com, on or before the close of business on April 1, 2024. To be eligible for inclusion in the proxy materials for the Annual Meeting, any such proposal must meet the requirements set forth in the rules and regulations of the SEC and the Company's bylaws, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 18, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: General Counsel